NVR-U.TI - AZIONI

TLO - TLO Delayed Price. Currency in EUR
82.16
+0.84 (+1.03%)
At close: 1:51PM CEST
Stock chart is not supported by your current browser
Previous Close81.32
Open81.64
Bid82.04 x 2000
Ask82.44 x 2500
Day's Range81.64 - 82.08
52 Week Range81.64 - 82.08
Volume87
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • McDonald’s posts earnings, Boeing has historical quarter, Novartis has a new plan
    Yahoo Finance Video5 months ago

    McDonald’s posts earnings, Boeing has historical quarter, Novartis has a new plan

    McDonald’s, Boeing, Novartis, Southwest Airlines and Foxconn are the companies to watch.

  • Davos 2019: Novartis CEO on company's focus
    Yahoo Finance Video5 months ago

    Davos 2019: Novartis CEO on company's focus

    Yahoo Finance's Julie Hyman discusses Novartis International's goals and partnership with Tilray with company CEO, Vasant Narasimhan.

  • Reuters4 months ago

    Clinigen agrees to buy U.S. rights to Novartis' cancer drug Proleukin

    (Reuters) - British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of ...

  • Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript
    Motley Fool5 months ago

    Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript

    LGND earnings call for the period ending December 31, 2018.

  • Reuters5 months ago

    Novartis CEO lauds Trump administration plan to overhaul rebates

    Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines..

  • Novartis CEO says U.S. rebate plan will return cash to patients
    Reuters5 months ago

    Novartis CEO says U.S. rebate plan will return cash to patients

    Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines.

  • Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript
    Motley Fool5 months ago

    Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript

    ARRY earnings call for the period ending December 31, 2018.

  • Novartis's Alcon eye-care unit to enter Swiss index after spin off
    Reuters5 months ago

    Novartis's Alcon eye-care unit to enter Swiss index after spin off

    Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland's 20 largest listed companies, market operator SIX said on Tuesday. Information about any other changes to SMI and Switzerland's other indexes will be released later, the bourse said. Novartis last year announced the spin off of Alcon to the Basel drugmaker's shareholders in the first half of this year.

  • Gene Therapy: Novartis Under The Microscope With Novel Treatment
    Investor's Business Daily5 months ago

    Gene Therapy: Novartis Under The Microscope With Novel Treatment

    The biotech world is feverishly awaiting the FDA's potential approval of a gene therapy called Zolgensma, a spinal muscular atrophy treatment, that is expected from Novartis in May.

  • Novartis Posts Earnings, Revenue Miss
    GuruFocus.com5 months ago

    Novartis Posts Earnings, Revenue Miss

    Novartis AG (NVS) reported fourth-quarter results before the opening bell on Wednesday. Warning! GuruFocus has detected 2 Warning Sign with NVS. By segment, sales in the innovative medicines business increased 5.4% year over year to $9.022 billion, sales from the Sandoz division fell 5.2% from the prior-year quarter to $2.459 billion and Alcon sales rose 1.5% to $1.788 billion.

  • Novartis Slides On Earnings Lag, But Sees 10 New Blockbusters By 2020
    Investor's Business Daily5 months ago

    Novartis Slides On Earnings Lag, But Sees 10 New Blockbusters By 2020

    Novartis earnings and sales lagged expectations early Wednesday, as the drug giant guided to low- to mid-single digit sales growth in 2019. Novartis stock was down on the news.

  • Reuters5 months ago

    Novartis CEO sees 'further conversation' on Sandoz future in 18 months

    Novartis Chief Executive Vas Narasimhan said he will be ready to discuss the future of generics unit Sandoz following a revamp due to take 18 months, while still calling the business "an integral part" of the Swiss drugmaker. "We consider Sandoz an integral part of Novartis, we're focused on transforming the business, making it an autonomous entity over the next 18 months that is able to compete as an independent unit within Novartis," Narasimhan said on a call with analysts on Wednesday.

  • Novartis 2019 growth outlook leaves investors wanting more
    Reuters5 months ago

    Novartis 2019 growth outlook leaves investors wanting more

    Novartis's 2019 sales and profit growth guidance disappointed investors seeking more from Chief Executive Vas Narasimhan's efforts to focus the Swiss drugmaker on high-tech medicines while shedding non-core assets. The company sees net sales growing by a low- to mid-single-digit percentage, with core operating income up by a mid-single-digit rate, Novartis said on Wednesday. Shares in the world's biggest prescription drugmaker had slipped 1.1 percent by 1305 GMT, lagging a 0.2 percent decline in the Stoxx European Health Care Index.

  • Associated Press5 months ago

    Novartis: 4Q Earnings Snapshot

    The Basel, Switzerland-based company said it had net income of 51 cents per share. Earnings, adjusted for non-recurring costs, were $1.24 per share. The results missed Wall Street expectations. The average ...

  • CNBC5 months ago

    Novartis earnings narrowly miss expectations, shares down 2%

    Swiss drugmaker Novartis reported slightly weaker-than-expected quarterly earnings on Wednesday, prompting shares to fall more than 2 percent shortly after the opening bell.

  • How Novartis Could Throw A Haymaker — And Slam Amgen's Sales
    Investor's Business Daily5 months ago

    How Novartis Could Throw A Haymaker — And Slam Amgen's Sales

    Amgen's biggest moneymaker could face biosimilar competition this year, an analyst said Monday as he downgraded Amgen stock. Novartis is nearing a court decision on its Enbrel biosimilar.

  • Novartis urges Britain to secure drug supplies before Brexit
    Reuters5 months ago

    Novartis urges Britain to secure drug supplies before Brexit

    The Swiss company, one of the world's biggest drugmakers, said the risk of Britain leaving the European Union, its biggest trading partner, without a deal had risen after Prime Minister Theresa May failed to get her deal through parliament last week. "Given the complex nature of the supply chain, government needs to implement a comprehensive continuity plan rapidly," Novartis said in a statement. Novartis's fastest-growing medicine is Cosentyx, the blockbuster medicine for psoriasis and other auto-immune disorders including ankylosing spondylitis.